Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com

StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report issued on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

ITCI has been the subject of a number of other reports. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $106.23.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Friday. The firm has a fifty day moving average price of $130.29 and a 200 day moving average price of $104.37. Intra-Cellular Therapies has a fifty-two week low of $64.09 and a fifty-two week high of $131.98. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several institutional investors and hedge funds have recently added to or reduced their stakes in ITCI. Accredited Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at about $28,000. MassMutual Private Wealth & Trust FSB boosted its stake in Intra-Cellular Therapies by 124.3% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 133 shares in the last quarter. GAMMA Investing LLC grew its holdings in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Intra-Cellular Therapies during the fourth quarter worth $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $97,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.